Pre-MENACTRIMS Symposium Novartis
BTK Inhibitors in MS: Defining the Next Chapter – From Emerging Evidence to Phase III Insights Non-Promotional Medical Satellite Symposium
Agenda
| Topic | Speaker | Duration |
|---|---|---|
| Welcome and Setting the Stage: BTK inhibition in the evolving MS landscape | Prof. Bassem Yamout – President, MENACTRIMS | 05 min |
| Understanding BTK Inhibition Across the MS Continuum: Potential, differences between BTK inhibitors, mechanisms, selectivity, and emerging evidence | Prof. Celia Oreja-Guevara | 20 min |
| From Emerging Evidence to Phase III Results: Efficacy and Safety of Remibrutinib vs. Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase III REMODEL-1/-2 Trials | Prof. Heinz Wiendl (Virtual) | 20 min |
| Expert Discussion and Q&A | All Faculty | 15 min |
Faculty
Chairperson
Speakers
Chairperson
Prof. Bassem I. Yamout
Professor of Neurology,
Director Neurology Institute
Director Neurology Institute
American University of Beirut & Harley Street Medical Center
Abu Dhabi, United Arab Emirates
Speaker
Prof. Celia Oreja-Guevara
Consultant Neurologist,
Professor of Neurology,
Vice Chair of Neurology
Professor of Neurology,
Vice Chair of Neurology
Hospital Universitario Clínico San Carlos,
Universidad Complutense de Madrid
Madrid, Spain
Speaker
Prof. Heinz Wiendl
Professor & Director of the Department of
Neurology and Neurophysiology
University Hospital Freiburg
Germany
Target Audience
- Specialists
- Neurologists
- Practitioners
- Researchers in the field of MS
Registration
Registration is complimentary and can be arranged via the online registration module upon registering for the congress pass.
What are the key takeaways from this Symposium?
By attending this symposium, you will:
- Explore the role of Bruton’s tyrosine kinase (BTK) inhibition in the evolving multiple sclerosis (MS) treatment landscape.
- Examine the potential of BTK inhibition across the MS continuum, including differences in mechanisms and selectivity between BTK inhibitors.
- Review emerging evidence on BTK inhibitors in MS.
- Review the Phase III REMODEL-1/-2 trial results on the efficacy and safety of remibrutinib versus teriflunomide in relapsing MS.
- Participate in expert discussion on the evidence presented and its implications for future MS care.
Abbreviations: MS: Multiple sclerosis;
BTK: Bruton’s tyrosine kinase.
Material ID: NOV/2026/ FA-50002840